StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.26+0.02 (+0.28%)

Close on Nov 18, 2026Market cap $479.26MP/E –Yield –

Regenxbio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Regenxbio's operating income for the twelve months ending Jun 30, 2026 was -$164.15M. For fiscal 2025 it was -$161.20M. The highest annual figure on record is $159.98M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$161.20M–
FY2024Dec 31, 2024-$233.35M–
FY2023Dec 31, 2023-$268.13M–
FY2022Dec 31, 2022-$262.88M-264.3%
FY2021Dec 31, 2021$159.98M–
FY2020Dec 31, 2020-$119.23M–
FY2019Dec 31, 2019-$149.00M-269.1%
FY2018Dec 31, 2018$88.10M–
FY2017Dec 31, 2017-$75.89M–
FY2016Dec 31, 2016-$65.34M–
FY2015Dec 31, 2015-$23.14M–
FY2014Dec 31, 2014-$3.68M–
FY2013Dec 31, 2013-$4.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.26M–
Q1 FY2026Mar 31, 2026-$83.36M-787.4%
Q4 FY2025Dec 31, 2025-$57.64M–
Q3 FY2025Sep 30, 2025-$52.41M–
Q2 FY2025Jun 30, 2025-$63.28M–
Q1 FY2025Mar 31, 2025$12.13M–
Q4 FY2024Dec 31, 2024-$51.37M–
Q3 FY2024Sep 30, 2024-$62.08M–
Q2 FY2024Jun 30, 2024-$56.04M–
Q1 FY2024Mar 31, 2024-$63.86M–
Q4 FY2023Dec 31, 2023-$63.90M–
Q3 FY2023Sep 30, 2023-$64.96M–
Q2 FY2023Jun 30, 2023-$73.11M–
Q1 FY2023Mar 31, 2023-$66.16M–
Q4 FY2022Dec 31, 2022-$57.77M-118.4%
Q3 FY2022Sep 30, 2022-$71.05M–
Q2 FY2022Jun 30, 2022-$62.53M–
Q1 FY2022Mar 31, 2022-$71.53M–
Q4 FY2021Dec 31, 2021$313.60M–
Q3 FY2021Sep 30, 2021-$57.35M-511.1%
Q2 FY2021Jun 30, 2021-$52.23M–
Q1 FY2021Mar 31, 2021-$44.04M–
Q4 FY2020Dec 31, 2020-$53.65M–
Q3 FY2020Sep 30, 2020$13.95M–
Q2 FY2020Jun 30, 2020-$41.83M–
Q1 FY2020Mar 31, 2020-$37.70M–
Q4 FY2019Dec 31, 2019-$40.32M-1745.9%
Q3 FY2019Sep 30, 2019-$35.90M–
Q2 FY2019Jun 30, 2019-$36.87M-680.7%
Q1 FY2019Mar 31, 2019-$35.91M-135.2%
Q4 FY2018Dec 31, 2018$2.45M–
Q3 FY2018Sep 30, 2018-$22.73M–
Q2 FY2018Jun 30, 2018$6.35M–
Q1 FY2018Mar 31, 2018$102.03M–
Q4 FY2017Dec 31, 2017-$16.60M–
Q3 FY2017Sep 30, 2017-$21.31M–
Q2 FY2017Jun 30, 2017-$15.06M–
Q1 FY2017Mar 31, 2017-$22.92M–
Q4 FY2016Dec 31, 2016-$20.47M–
Q3 FY2016Sep 30, 2016-$18.67M–

More Regenxbio figures

See a number that looks wrong?